Morgan Stanley Alnylam Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 618,563 shares of ALNY stock, worth $154 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

618,563

Previous 741,514 16.58%

Holding current value

$154 Million

Previous $180 Million 5.57%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $28.7 Million - $35.3 Million	-122,951 Reduced 16.58%	618,563 $170 Million
Q2 2024 Oct 17, 2024	BUY	$143.31 - $247.0 $9.49 Million - $16.4 Million	66,233 Added 9.81%	741,514 $180 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $9.49 Million - $16.4 Million	66,233 Added 9.81%	741,514 $180 Million
Q1 2024 Oct 17, 2024	SELL	$146.51 - $198.2 $9.7 Million - $13.1 Million	-66,233 Reduced 8.93%	675,281 $101 Million
Q1 2024 Aug 16, 2024	SELL	$146.51 - $198.2 $19.2 Million - $26 Million	-131,314 Reduced 16.28%	675,281 $101 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $19.2 Million - $26 Million	-131,314 Reduced 16.28%	675,281 $101 Million
Q4 2023 Aug 16, 2024	BUY	$151.41 - $196.57 $9.85 Million - $12.8 Million	65,081 Added 8.78%	806,595 $154 Million
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $61 Million - $79.2 Million	-402,788 Reduced 33.31%	806,595 $154 Million
Q3 2023 Nov 15, 2023	SELL	$170.77 - $211.65 $115 Million - $142 Million	-671,423 Reduced 35.7%	1,209,383 $214 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $120 Million - $138 Million	649,991 Added 52.81%	1,880,806 $357 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $29.2 Million - $37.6 Million	-159,825 Reduced 11.49%	1,230,815 $247 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $20.1 Million - $26.1 Million	-108,119 Reduced 7.21%	1,390,640 $330 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $51.3 Million - $85.9 Million	370,144 Added 32.8%	1,498,759 $300 Million
Q2 2022 Oct 27, 2022	BUY	$120.42 - $169.29 $33.7 Million - $47.4 Million	279,958 Added 32.99%	1,128,615 $165 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $33.7 Million - $47.4 Million	279,958 Added 32.99%	1,128,615 $165 Million
Q1 2022 Oct 27, 2022	SELL	$127.18 - $173.91 $35.6 Million - $48.7 Million	-279,958 Reduced 24.81%	848,657 $139 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $27.6 Million - $37.7 Million	-217,032 Reduced 20.37%	848,657 $139 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $130 Million - $171 Million	-815,190 Reduced 43.34%	1,065,689 $181 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $319 Million - $391 Million	1,880,879 New	1,880,879 $355 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account